Royal Bank Of Canada restated their hold rating on shares of DaVita HealthCare Partners Inc. (NYSE:DVA) in a research note published on Wednesday. Royal Bank Of Canada currently has a $64.00 price objective on the stock.

DVA has been the subject of several other research reports. BidaskClub cut shares of DaVita HealthCare Partners from a sell rating to a strong sell rating in a research report on Saturday, August 5th. Jefferies Group LLC cut shares of DaVita HealthCare Partners from a buy rating to a hold rating and increased their target price for the company from $64.89 to $70.00 in a research report on Monday, June 26th. Zacks Investment Research cut shares of DaVita HealthCare Partners from a hold rating to a sell rating in a research report on Tuesday, July 4th. Goldman Sachs Group, Inc. (The) reissued a sell rating and set a $62.00 target price on shares of DaVita HealthCare Partners in a research report on Thursday, May 25th. Finally, TheStreet cut shares of DaVita HealthCare Partners from a b rating to a c+ rating in a research report on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $68.88.

Shares of DaVita HealthCare Partners (NYSE:DVA) traded up 0.03% during mid-day trading on Wednesday, reaching $57.44. 32,847 shares of the company’s stock traded hands. The firm has a market capitalization of $10.98 billion, a price-to-earnings ratio of 8.75 and a beta of 0.91. The stock has a 50-day moving average price of $59.47 and a 200 day moving average price of $64.75. DaVita HealthCare Partners has a 12-month low of $54.50 and a 12-month high of $70.16.

DaVita HealthCare Partners (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 1st. The company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.02. DaVita HealthCare Partners had a net margin of 8.68% and a return on equity of 14.02%. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same quarter in the prior year, the company earned $1.01 EPS. The company’s revenue was up 4.3% compared to the same quarter last year. Analysts anticipate that DaVita HealthCare Partners will post $3.59 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.thecerbatgem.com/2017/09/07/davita-healthcare-partners-inc-dva-receives-hold-rating-from-royal-bank-of-canada.html.

Several hedge funds and other institutional investors have recently bought and sold shares of DVA. Profund Advisors LLC raised its holdings in shares of DaVita HealthCare Partners by 4.7% in the first quarter. Profund Advisors LLC now owns 6,328 shares of the company’s stock worth $430,000 after buying an additional 282 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of DaVita HealthCare Partners by 33.5% in the first quarter. Janney Montgomery Scott LLC now owns 13,261 shares of the company’s stock worth $901,000 after buying an additional 3,325 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of DaVita HealthCare Partners by 51.6% in the first quarter. Russell Investments Group Ltd. now owns 205,793 shares of the company’s stock worth $13,988,000 after buying an additional 70,037 shares during the last quarter. Sumitomo Mitsui Asset Management Company LTD raised its holdings in shares of DaVita HealthCare Partners by 9.6% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 13,843 shares of the company’s stock worth $940,000 after buying an additional 1,213 shares during the last quarter. Finally, Wells Fargo & Company MN raised its holdings in shares of DaVita HealthCare Partners by 27.2% in the first quarter. Wells Fargo & Company MN now owns 674,233 shares of the company’s stock worth $45,827,000 after buying an additional 144,198 shares during the last quarter. 83.43% of the stock is owned by institutional investors and hedge funds.

About DaVita HealthCare Partners

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Stock Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related stocks with our FREE daily email newsletter.